DNA vs GLUE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

DNA

35.0
AI Score
VS
GLUE Wins

GLUE

42.3
AI Score

Investment Advisor Scores

DNA

35score
Recommendation
SELL

GLUE

42score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA GLUE Winner
Net Income -313,000 -87.90M DNA
Operating Income -315.28M -99.16M GLUE
ROE -0.1% -18.0% DNA
ROA -0.0% -12.7% DNA
Total Assets 1.12B 691.16M DNA
Cash 167.20M 90.10M DNA
Current Ratio 4.92 10.58 GLUE
Free Cash Flow -178.72M -88.07M GLUE

Relative Price Performance (Last 90 Days)

DNA 1M: +75.7% · 3M: +22.2% GLUE 1M: -26.2% · 3M: -54.8%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 75

RSI (14): 74.6 · Price: $12.35

GLUE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -22.7%), weak momentum, RSI 24

RSI (14): 23.7 · Price: $10.50

Fundamentals Snapshot

Metric DNA GLUE
Market Cap — —
Forward P/E -4.3 -5.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.5% -0.6%
Gross Margin 0.7% -4.7%
Operating Margin -2.8% -5.5%
EPS -5.19 -1.75
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GLUE is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.